Am. J. Respir. Crit. Care Med., Volume 159, Number 1, January 1999, 295-300

A Tuberculin Screening and Isoniazid Preventive Therapy Program in an Inner-City Population

NAOMI N. BOCK, BRIAN S. METZGER, JANE R. TAPIA, and HENRY M. BLUMBERG

Division of Infectious Diseases, Emory University School of Medicine and Grady Memorial Hospital, Atlanta, Georgia

As tuberculosis transmission decreases, case rates decline and an increasing proportion of cases arises from the pool of persons with latent infection. Elimination of tuberculosis will require preventing disease from developing in infected persons. From 1994 to 1996 the Atlanta TB Prevention Coalition conducted a community-based tuberculin screening and isoniazid preventive therapy project among high-risk inner-city residents of Atlanta, Georgia. We established screening centers in outpatient waiting areas of the public hospital serving inner-city residents, the city jail, clinics serving the homeless, and with outreach teams in neighborhoods frequented by drug users. All services were provided free. A total of 7,246 persons participated in tuberculin testing; 4,701 (65%) adhered with skin test reading, 809 (17%) had a positive test, 409 (50%) fit current guidelines for isoniazid preventive therapy, 84 (20%) we intended to treat completed therapy. The major limitations of this community-based tuberculin screening and preventive therapy project were the low proportion of infected individuals who were eligible for isoniazid preventive therapy and the poor adherence with a complete regimen among those we intended to treat. For community-based programs to be efficacious, preventive therapy regimens that are of shorter duration and safe for older persons will need to be implemented.

This article has been cited by other articles:

				H. Kornfeld An Ounce of Tuberculosis Prevention Chest, April 1, 2008; 133(4): 835 - 836. [Full Text] [PDF]

				A. Kwara, J. S. Herold, J. T. Machan, and E. J. Carter Factors Associated With Failure To Complete Isoniazid Treatment for Latent Tuberculosis Infection in Rhode Island Chest, April 1, 2008; 133(4): 862 - 868. [Abstract] [Full Text] [PDF]

				F. K. Shieh, G. Snyder, C. Robert Horsburgh, J. Bernardo, C. Murphy, and J. J. Saukkonen Predicting Non-Completion of Treatment for Latent Tuberculous Infection: A Prospective Survey Am. J. Respir. Crit. Care Med., September 15, 2006; 174(6): 717 - 721. [Abstract] [Full Text] [PDF]

				B J Marais, S. van Zyl, H S Schaaf, M van Aardt, R P Gie, and N Beyers Adherence to isoniazid preventive chemotherapy: a prospective community based study Arch. Dis. Child., September 1, 2006; 91(9): 762 - 765. [Abstract] [Full Text] [PDF]

				T. R. Sterling, J. Bethel, S. Goldberg, P. Weinfurter, L. Yun, C. R. Horsburgh, and the Tuberculosis Epidemiologic Studies Consortium The Scope and Impact of Treatment of Latent Tuberculosis Infection in the United States and Canada Am. J. Respir. Crit. Care Med., April 15, 2006; 173(8): 927 - 931. [Abstract] [Full Text] [PDF]

				American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: Controlling Tuberculosis in the United States Am. J. Respir. Crit. Care Med., November 1, 2005; 172(9): 1169 - 1227. [Full Text] [PDF]

				Pediatric Tuberculosis Collaborative Group Targeted Tuberculin Skin Testing and Treatment of Latent Tuberculosis Infection in Children and Adolescents Pediatrics, October 1, 2004; 114(4/S2): 1175 - 1201. [Abstract] [Full Text] [PDF]

				C. R. Horsburgh Jr. Priorities for the Treatment of Latent Tuberculosis Infection in the United States N. Engl. J. Med., May 13, 2004; 350(20): 2060 - 2067. [Abstract] [Full Text] [PDF]

				M. Narita, M. Kellman, D. L. Franchini, M. E. McMillan, E. S. Hollender, and D. Ashkin Short-Course Rifamycin and Pyrazinamide Treatment for Latent Tuberculosis Infection in Patients With HIV Infection: The 2-Year Experience of a Comprehensive Community-Based Program in Broward County, Florida Chest, October 1, 2002; 122(4): 1292 - 1298. [Abstract] [Full Text] [PDF]

				N. W. Schluger Challenges of Treating Latent Tuberculosis Infection Chest, June 1, 2002; 121(6): 1733 - 1735. [Full Text] [PDF]

				W. J. BURMAN and R. R. REVES Hepatotoxicity from Rifampin Plus Pyrazinamide . Lessons for Policymakers and Messages for Care Providers Am. J. Respir. Crit. Care Med., October 1, 2001; 164(7): 1112 - 1113. [Full Text] [PDF]

				G. Antonucci, E. Girardi, M. Raviglione, P. Vanacore, G. Angarano, A. Chirianni, G. Pagano, F. Suter, F.N. Lauria, G. Ippolito, et al. Guidelines of tuberculosis preventive therapy for HIV-infected persons: a prospective, multicentre study Eur. Respir. J., August 1, 2001; 18(2): 369 - 375. [Abstract] [Full Text] [PDF]

				N. N. Bock, T. Rogers, J. R. Tapia, G. D. Herron, B. DeVoe, and L. J. Geiter Acceptability of Short-Course Rifampin and Pyrazinamide Treatment of Latent Tuberculosis Infection Among Jail Inmates Chest, March 1, 2001; 119(3): 833 - 837. [Abstract] [Full Text] [PDF]

				Targeted Tuberculin Testing and Treatment of Latent Tuberculosis Infection . This Official Statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. This is a Joint Statement of the American Thoracic Society (ATS) and the Centers for Disease Control and Prevention (CDC). This Statement was endorsed by the Council of the Infectious Diseases Society of America (IDSA), September 1999, and the sections of this Statement as it relates to infants and children were endorsed by the American Academy of Pediatrics (AAP), August 1999. Am. J. Respir. Crit. Care Med., April 1, 2000; 161(4): S221 - 247. [Full Text] [PDF]

				M. E. Kimerling, J. T. Barker, F. Bruce, N. L. Brook, and N. E. Dunlap Preventable Childhood Tuberculosis in Alabama: Implications and Opportunity Pediatrics, April 1, 2000; 105(4): 53e - 53. [Abstract] [Full Text]